Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2022

View Archived Issues

New free fatty acid receptor 1 agonists identified at Rezubio Pharmaceuticals

Shanghai Zheye Biotechnology describes new anticancer compounds

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent TLR7/8/9 antagonists

Apoptosis regulator Bcl-2 inhibitors discovered at Beijing Innocare Medical Technology

China Hinye Pharmaceutical presents prodrugs of the active metabolite of clopidogrel

Mouse model of SARS-CoV-2 infection shows COVID-19-like disease is dependent on ACE2

STING signaling in beta cells maintains glucose homeostasis

Type II interferon restricts severity of NMO in a new preclinical model

Bryostatin-1 promotes regenerative phenotype within microglia and CNS macrophages

Novel murine model developed to test CNS-penetrant BTK inhibitors

BAFF biomarker tied to severity of allergic rhinitis

Shionogi and Ube collaborate to advance S-337395 toward clinic for RSV

Study identifies potential new bone disease target

Murine model reveals aging to promote autoimmune encephalomyelitis with meningeal inflammation

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026